Cardiovascular morbidity and mortality in patients in Wales, UK with resistance to thyroid hormone (3 (RTH(3): a linked-record cohort study

Background Individuals with resistance to thyroid hormone owing to mutations in the thyroid hormone receptor 13 gene (RTH13) exhibit impaired tissue sensitivity to thyroid hormones, but retain sensitivity in cardiac tissue. Long-term health and survival outcomes in this rare disorder have not been evaluated. We investigated all-cause mortality and cardiovascular event risk in a cohort of patients with RTH13, followed-up in UK endocrine clinics.Methods In a retrospective cohort design, we linked genetically confirmed patients with RTH13 and age-matched and sex-matched population controls to outcomes in datasets within the Welsh Secure Anonymised Information Linkage (SAIL) Databank. Kaplan-Meier and Cox regression models analysed associations of RTH13 with all-cause mortality and cardiovascular events.Findings We identified 61 patients with a genetic diagnosis of RTH13 between Jan 1, 1997, and Dec 31, 2019, and matched them with 2750 controls. Compared with controls, patients exhibited increased risks for all-cause mortality (hazard ratio [HR] 2 & BULL;84, 95% CI 1 & BULL;59-5 & BULL;08), atrial fibrillation (10 & BULL;56, 4 & BULL;72-23 & BULL;63), heart failure (HR 6 & BULL;35, 95% CI 2 & BULL;26-17 & BULL;86), and major adverse cardiovascular events (MACE), comprising cardiovascular death, acute myocardial infarction, heart failure, or strokes (HR 3 & BULL;49, 95% CI 2 & BULL;04-5 & BULL;99). The median age of first occurrence of any adverse event was 11 years earlier in patients (56 years, 95% CI 44-65) compared with controls (67 years, 65-70). Cubic spline analyses showed positive associations between FT4 concentrations at diagnosis and mortality or MACE, with FT4 concentration of 30 pmol/L or greater conferring increased risk. Compared with no intervention, treatment with antithyroid drugs, surgery or radioiodine gland ablation, or thyroxine did not control thyroid hormone excess.Interpretation We have documented reduced survival and increased cardiovascular morbidity in a cohort of patients with RTH13 for the first time. These outcomes might be driven by lifelong cardiac exposure to thyroid hormone excess; and effective therapies, targeting hormone resistant pathways, could potentially curtail this risk.Funding Royal College of Physicians, Wellcome Trust Investigator Award, and NIHR Cambridge Biomedical Research Centre.Copyright & COPY; 2023 Published by Elsevier Ltd. All rights reserved.